CARSK stands for the "Canadian-Australasian Randomised Trial of Screening Kidney Transplant Candidates for Coronary Artery Disease."
Study overview
CARSK is an investigator-initiated, multicentre, non-inferiority, two-parallel-arm randomized trial. It aims to test the hypothesis that after screening for waitlist entry, no further screening for coronary artery disease (CAD) is not inferior to the current standard care, which is screening all asymptomatic waitlisted patients for CAD at regular intervals.

Additionally, it will compare the benefits and costs of not screening versus regular CAD screening from a health system perspective.

Why is this trial important?
Cardiovascular disease is the commonest cause of death while on the kidney transplant waitlist and after transplantation. Current standard care involves screening for coronary artery disease prior to waitlist entry, then every 1-2 years, according to perceived risk, until transplanted. This current screening strategy is not evidence based, has substantial known and potential harms, and is very costly.

Trial registration
The trial is registered at ANZCTR and Please see ANZCTR and for more information.
ACTRN126160007364488 (WWW.ANZCTR.ORG.AU)
Trial funding
NHMRC Funded Clinical Trial Project Grant #1084454
CIHR Grant #389992

Worldwide Randomisations as of August 1st 2021

  • Auckland City Hospital in Auckland, NZ has randomised 205 participants.
  • Westmead Hospital in Sydney, Australia has randomised 167 participants.
  • St. Paul's Hospital in Vancouver, Canada has randomised 151 participants.
  • Royal Prince Alfred Hospital in Sydney, Australia has randomized 147 participants.
  • Vancouver General Hospital in Vancouver, Canada has randomised 92 participants
  • The University Health Network in Toronto, Canada has randomised 50 participants.
  • Bellvitge Hospital in Barcelona, Spain has randomised 46 participants.
  • Royal North Shore Hospital in Sydney, Australia has randomised 37 participants.
  • Wellington Hospital in Wellington, NZ has randomised 26 participants as of October 2019.
  • London Health Sciences Centre in London, Canada has randomised 27 participants.
  • St. George Hospital in Kogorah, Australia has randomised 24 participants.
  • St Joseph's Healthcare in Hamilton, Canada has randomised 24 participants.
  • Box Hill Hospital in Melbourne, Australia has randomised 23 participants.
  • The Ottawa Hospital in Ottawa, Canada has randomised 22 participants.
  • The George Washington University in Washington, DC, USA has randomised 20 participants.
  • Monash Medical Centre in Clayton, Australia has randomised 19 participants.
  • Austin Hospital in Heidelberg, Australia has randomised 16 participants.
  • Dunedin Hospital in Dunedin, NZ has randomised 15 participants.
  • University of Montreal, Maisonneuve-Rosemont in Montreal, Canada has randomised 16 participants.
  • Queen Elizabeth II Health Sciences in Halifax, Canada has randomised 15 participants.
  • Royal Adelaide Hospital in Adelaide, Australia has randomised 13 participants.
  • University of Montreal (CHUM) in Montreal, Canada has randomised 13 participants.
  • Royal University Hospital in Saskatoon, Canada has randomised 12 participants.
  • Christchurch Hospital in Christchurch, NZ has randomised 10 participants.
  • Prince of Wales Hospital in Randwick, Australia has randomised 10 participants.
  • McGill University Health Centre in Montreal, Canada has randomised 6 participants.
  • St Michael's Hospital in Toronto, Canada has randomised 8 participants.
  • Laval University in Laval, Canada has randomised 5 participants.
  • Wollongong Hospital in Wollongong, Australia has randomised 4 participants.
  • Kingston General Hospital in Kingston, Canada has randomised 6 participants.

Featured Sites

About the logo
The logo is two overlapping kidneys in the shape of a heart. The colours are those of the flags of New Zealand, Australia, and Canada, the main participating countries in this trial. Logo design by Jesse Horner.